Também conhecido como
Somatomedin C
Nome formal
Insulin-like Growth Factor - 1
Este artigo foi revisto pela última vez em
Este artigo foi modificado pela última vez em 10 de Julho de 2017.
At a Glance
Why Get Tested?
To identify diseases and conditions caused by deficiencies and overproduction of growth hormone (GH), to evaluate pituitary function, and to monitor the effectiveness of GH treatment
When To Get Tested?
As part of an evaluation of pituitary function; when you have symptoms of slow growth, short stature, and delayed development (in children) or decreased bone density, reduced muscle strength, and increased lipids (in adults) that suggest insufficient GH and IGF-1 production; when you have symptoms of gigantism (in children) or acromegaly (in adults) that suggest excess GH and IGF-1 production; during and after treatment for GH abnormalities
Sample Required?
A blood sample drawn from a vein in your arm or by a fingerstick (in children)
What is being tested?
The insulin-like growth factor-1 (IGF-1) test is an indirect measure of the average amount of growth hormone (GH) being produced by the body. IGF-1 and GH are peptide hormones, small proteins that are vital for normal bone and tissue growth and development. GH is produced by the pituitary gland, a grape-sized gland located at the base of the brain behind the bridge of your nose. GH is secreted into the bloodstream in pulses throughout the day and night with peaks that occur mostly during the night. IGF-1 is produced by the liver and to a lesser degree by skeletal muscles, primarily in response to GH stimulation. It mediates many of the actions of GH, stimulating the growth of bones and other tissues and promoting the production of lean muscle mass. IGF-1 mirrors GH excesses and deficiencies, but its level is stable throughout the day, making it a useful indicator of average GH levels.

Like GH, IGF-1 levels are normally low in early childhood, increase gradually during childhood, peak during puberty, and then decline in adult life. Deficiencies in GH and IGF-1 may be caused by conditions such as hypopituitarism or by the presence of a non-GH-producing pituitary tumor that damages hormone-producing cells. Deficiencies in IGF-1 also occur where there is a lack of responsiveness to GH. This insensitivity may be primary (genetic) or secondary to conditions such as malnutrition and chronic diseases.

Deficiencies early in life can inhibit bone growth and overall development and can result in a child with a shorter than normal stature. In adults, decreased production can lead to low bone densities, less muscle mass, and altered lipids.

Excess GH and IGF-1 can cause abnormal growth of the skeleton and other signs and symptoms characteristic of gigantism and acromegaly. In children, gigantism causes bones to grow longer, resulting in a very tall person with large feet and hands. In adults, acromegaly causes bones to thicken and soft tissues, such as the nose, to swell. Both conditions can lead to enlarged organs, such as the heart, and to other complications such as type 2 diabetes, increased cardiovascular disease risk, high blood pressure, arthritis, and a decreased life span. The most common reason for the pituitary to secrete excessive amounts of GH is a GH-producing pituitary tumor (usually benign). Frequently, the tumor can be surgically removed and/or treated with drugs or radiation. In most cases, this will cause GH and IGF-1 levels to return to normal or near normal levels.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in your arm or by a fingerstick (in children).

Is any test preparation needed to ensure the quality of the sample?

In general, no test preparation is needed; however, since this test may be performed at the same time as others, fasting for at least 12 hours may be required.
Accordion Title
Common Questions
  • How is it used?
    IGF-1 is measured to help diagnose the cause of growth abnormalities and to evaluate pituitary function. It is not diagnostic of GH deficiency but may be ordered along with GH stimulation tests to offer additional information. IGF-1 levels and the measurement of GH can also provide information related to GH insensitivity.

    IGF-1 may be ordered with other pituitary hormone tests, such as adrenocorticotropic hormone (ACTH), to help diagnose hypopituitarism. It may be used to monitor the effectiveness of treatment for growth hormone deficiencies and growth hormone insensitivity.

    IGF-1 testing and a GH suppression test can be used to detect a GH-producing pituitary tumor. Its presence is then confirmed with imaging scans that help identify and locate the tumor. If surgery is necessary, GH and IGF-1 levels are measured after the tumor’s removal to determine whether or not all of it was successfully removed. Drug and/or radiation therapy may be used in addition to (or sometimes instead of) surgery to try to decrease GH production and return IGF-1 to normal or near normal concentrations. IGF-1 may be used to monitor the effectiveness of this therapy at regular intervals for years afterward to monitor GH production and to detect tumor recurrence.

  • When is it ordered?
    IGF-1 testing may be ordered, along with a GH stimulation test, when a child has symptoms of GH deficiency, such as a slowed growth rate and short stature. They also may be ordered when adults have symptoms that the doctor suspects may be due to a GH deficiency. An IGF-1 also may be ordered when a doctor suspects that a person has an underactive pituitary gland and at intervals to monitor patients on GH therapy.

    IGF-1 testing may be ordered, along with a GH suppression test, when a child has symptoms of gigantism, an adult shows signs of acromegaly, and/or when a doctor suspects that a patient has hyperpituitarism.

    When a GH-producing pituitary tumor is found, GH and IGF-1 are ordered after the tumor is surgically removed to determine whether all of the tumor has been extracted. IGF-1 also is ordered at regular intervals when a patient is undergoing the drug and/or radiation therapy that frequently follow tumor surgery.

    IGF-1 levels may be ordered at regular intervals for many years to monitor a patient’s GH production and to watch for pituitary tumor recurrence.

  • What does the test result mean?
    Normal concentrations of IGF-1 must be considered in context. Some patients can have a GH deficiency and still have a normal IGF-1 concentration.

    Decreased IGF-1
    If IGF-1 concentrations are decreased, then it is likely that there is a deficiency of GH (GH Deficiency; GHD) or an insensitivity to GH. If this is in a child, the GH deficiency may have already caused short stature and delayed development and may be treated with GH supplementation. Adults will have an age-related decrease in production, but lower than expected concentrations may reflect a GH deficiency or insensitivity.

    If a decrease in IGF-1 is due to a more general decrease in pituitary function (hypopituitarism), then several of the patient’s pituitary hormones will need to be evaluated and may be supplemented to bring them up to normal levels. Reduced pituitary function may be due to inherited defects or can rise as a result of pituitary damage following conditions such as trauma, infections, and inflammation.

    Decreased levels of IGF-1 also may be seen with nutritional deficiencies (including anorexia nervosa), chronic kidney or liver disease, inactive/ineffective forms of GH, and with high doses of estrogen.

    Increased IGF-1
    Elevated levels of IGF-1 usually indicate an increased production of GH. Since GH levels vary throughout the day, IGF-1 concentrations are a reflection of average GH production, not of the actual amount of GH in the blood. This is accurate up to the point at which the liver’s capacity to produce IGF-1 is reached. With severely increased GH production, IGF-1 levels will stabilize at an elevated maximum concentration.

    Increased concentrations of GH and IGF-1 are normal during puberty and pregnancy but otherwise are most frequently due to pituitary tumors (usually benign). If other pituitary hormones are also abnormal, then the patient may have a condition causing general hyperpituitarism.

    If IGF-1 is still elevated after the surgical removal of a pituitary tumor, then the surgery may not have been fully effective. Decreasing IGF-1 concentrations during subsequent drug and/or radiation therapies indicate that the treatment is lowering GH production. If levels of IGF-1 become “normalized,” then the patient is no longer producing excess amounts of GH. When a patient is undergoing long term monitoring, an increase in IGF-1 levels may indicate a recurrence of the pituitary tumor.

  • Is there anything else I should know?
    If an IGF-1 level is normal and the doctor still strongly suspects a GH deficiency, then he may order another test, an IGF BP 2 or IGF BP 3 (insulin-like growth factor binding protein 2 or 3), to help confirm the GH deficiency.
  • What signs and symptoms are seen with deficient GH and IGF-1?
    In children, the following may indicate GH and/or IGF-1 deficiency:
  • Slowed growth rate in early childhood relative to group norms
  • Shorter stature than others of the same chronological age
  • Delayed puberty
  • x-rays showing delayed bone development.

  • In adults, abnormally low levels of GH and/or IGF-1 may cause subtle, nonspecific symptoms such as:
  • Decreased bone density
  • Fatigue
  • Adverse lipid changes
  • Reduced exercise tolerance.
  • What signs and symptoms are seen with excess GH and IGF-1 production?
    In a child, it is unusual tallness that is often first noticed. With an adult, it may be more subtle: a larger nose, thicker lips, a more prominent jaw, or rings and shoes that no longer fit. Other signs and symptoms may include:
  • Deepened, husky voice
  • Enlarged organs - liver, heart, kidneys, and spleen
  • Enlarged tongue
  • Erectile dysfunction
  • Fatigue
  • Headaches and visual disturbances
  • Joint pain and swelling
  • Menstrual cycle irregularities
  • Muscle weakness
  • Snoring
  • Sweating and body odor
  • Thickening of the skin, skin tags
  • Trapped nerves (Carpal tunnel syndrome)
  • How long do I have to be monitored?
    As long as you are considered to have abnormal (low or high) GH production or are receiving GH replacement therapy, your IGF-1 will need to be monitored.
  • View Sources
    Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

    Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

    Thorner, M. et. al. (2003 September 24). Advanced Strategies for Achieving IGF-I Control in Acromegaly [71 paragraphs]. The Endocrine Society [CME on Medscape]. Available FTP: http://www.medscape.com/viewprogram/2638_pnt

    Cromie, W. (1999 April 22). Growth Factor Raises Cancer Risk [23 paragraphs]. Harvard Gazette Archives [On-line article]. Available FTP: http://www.news.harvard.edu/gazette/1999/04.22/igf1.story.html

    IGF-1 (Insulin-Like Growth Factor 1) [4 paragraphs]. ARUP Guide to Clinical Laboratory Testing. [On-line information]. Available FTP: http://www.arup-lab.com/guides/clt/tests/clt_al3b.jsp#1349162

    Growth Hormone (Human Growth Hormone, HGH, Somatotropin) [4 paragraphs]. Acromegaly, ARUP Guide to Clinical Laboratory Testing. [On-line information]. Available FTP: http://www.arup-lab.com/guides/clt/tests/clt_al3b.jsp#1349162

    (2002 Int J Cancer). Elevated IGF-1 Linked to Risk of Ovarian Cancer in Younger Women [5 paragraphs]. National Cancer Institute, CTEP, From Int J Cancer 101:549-554. [On-line information]. Available FTP: http://ctep.info.nih.gov/resources/gcig/news102902.html

    Mayo Clinic Staff (2003 May 08). Acromegaly [26 paragraphs]. MayoClinic.com [On-line information]. Available FTP: http://www.mayoclinic.com/invoke.cfm?id=DS00478

    (2002 June). Acromegaly [24 paragraphs]. NIDDK, NIH Publication No. 02-3924 [On-line information]. Available FTP: http://www.niddk.nih.gov/health/endo/pubs/acro/acro.htm

    (2002) Acromegaly [13 paragraphs] MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/000321.htm

    (2004 January 23). Unsportsmanlike behavior [7 paragraphs]. The Washington Times [On-line article]. Available FTP: http://www.washingtontimes.com/functions/print.php?StoryID=20040122-082812-2585r

    Kass, L. and Council (2003 October). Chapter Three, Superior Performance [121 paragraphs]. Beyond Therapy: Biotechnology and the Pursuit of Happiness, The President's Council on Bioethics [On-line report]. Available FTP: http://bioethicsprint.bioethics.gov/reports/beyondtherapy/index.html

    (2003 May 30). Race to develop drug abuse test [19 paragraphs]. BBC News [On-line article]. Available FTP: http://news.bbc.co.uk/1/hi/health/2946344.stm

    Acromegaly and Gigantism [15 paragraphs]. Merck Manual Second Home Edition [On-line information]. Available FTP: http://www.merck.com/mrkshared/mmanual_home2/sec13/ch162/ch162e.jsp

    Clemmons, D. (2004 January 1). The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity [6 paragraphs]. J Clin Invest 113(1): 25-27 [On-line article]. Available FTP: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=300772

    (2003 April 14, Updated). Growth Hormone [24 paragraphs]. Index of the Hypothalamus and Pituitary Gland, Colorado State University Hypertext [On-line information]. Available FTP: http://arbl.cvmbs.colostate.edu/hbooks/pathphys/endocrine/hypopit/gh.html

    (2003 February 18, Updated). Growth Hormone and Aging [9 paragraphs]. Index of the Hypothalamus and Pituitary Gland, Colorado State University Hypertext [On-line information]. Available FTP: http://arbl.cvmbs.colostate.edu/hbooks/pathphys/endocrine/hypopit/ghaging.html

    Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 879 – 880.

    Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC. Grenache, D and Willis, M., Chapter 31, Hypothalamic, Pituitary, and Gonadal Disorders. Pp 351-363.

    Wu, A. (2006). Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders Elsevier, St. Louis, Missouri. Pp 626-628.

    Sheppard, M. (2007 April 3). Growth Hormone Assay Standardization: An Important Clinical Advance [7 paragraphs]. Medscape from Clin Endocrinol. 2007;66(2):157-161. [On-line information]. Accessed on: 8/18/07 Available FTP: http://www.medscape.com/viewarticle/553885

    (2007 April). Acromegaly [24 paragraphs]. NIDDK, NIH Publication No. 02-3924 [On-line information, accessed September 2007]. Available FTP: http://www.niddk.nih.gov/health/endo/pubs/acro/acro.htm